Evidence map›Paper›PMID 42101375›Full record

ArticleBlood advances2026

Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Julian Grabek, Jasmin Straube, Leanne Cooper, Rohit Haldar, Ranran Zhang, Inken Dulige, Matthew Barker, Will Gatehouse, Helen Christensen, Gerlinda Amor and 6 more

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Julian GrabekCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0001-5168-050X
Jasmin StraubeCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-1748-0659
Leanne CooperCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Rohit HaldarCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Ranran ZhangCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-5273-3615
Inken DuligeCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0009-0001-1923-6262
Matthew BarkerCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0009-0009-5304-5812
Will GatehouseCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Helen ChristensenCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Gerlinda AmorCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Victoria Y LingCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0001-9757-1229
Caroline McNamaraCancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
David M RossDepartment of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia.ORCID 0000-0001-7171-2935
Andrew PerkinsAlfred Hospital, Melbourne, VIC, Australia.ORCID 0000-0003-3644-7093
Megan J BywaterCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-7466-6927
Steven W LaneCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-8050-6209

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractMyeloproliferative neoplasms (MPNs) are caused by acquired mutations in hematopoietic stem and progenitor cells (HSPCs). The acquisition of additional mutations, such as TP53, and the overall mutational burden influence a patient's risk of disease progression to lethal post-MPN acute myeloid leukemias (AML). Recent technological advancements in linking single-cell gene expression with genotype have improved our understanding of tumor heterogeneity. However, current methodologies have limitations in simultaneously genotyping low-expression genes (such as JAK2) alongside other pathogenic loci. To address this, we developed a novel long-read genotyping pipeline of complementary DNA transcripts (long-read genotyping of transcripts [LOTR]-Seq), which can genotype the full length of expressed transcripts from 30 genes at once. Using LOTR-Seq, we genotyped HSPCs at the JAK2V617 locus in 9075 single cells from 8 patients with chronic-phase MPN (CP-MPN) and in 5016 cells from 4 patients with post-MPN AML. We then linked the mutations to the single-cell transcriptomes of 29 712 JAK2V617F-driven CP-MPN cells and 16 895 post-MPN AML cells. In our analysis of post-MPN AML, we identified 9 mutated loci across 6 genes (JAK2, IDH1/2, TP53, SRSF2, and U2AF1) and linked these mutations to specific transcriptional phenotypes. Overall, LOTR-Seq provides novel insights into the evolution of post-MPN AML.

Indexed as

Clonal EvolutionGenotyping TechniquesLeukemia, Myeloid, AcuteMyeloproliferative DisordersSingle-Cell AnalysisGenotypeHumansJanus Kinase 2MutationSingle-Cell Gene Expression AnalysisJanus Kinase 2

Identifiers

PMID42101375
PMCPMC13382927

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.